Effects of glucosamine and chondroitin supplementation on knee osteoarthritis: An analysis with marginal structural models

Arthritis and Rheumatology

Volumn 67, Issue 3, 2015, Pages 714-723

  Yang, Shibing ^a   Eaton, Charles B ^b   McAlindon, Timothy E ^c   Lapane, Kate L ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN; GLUCOSAMINE; DRUG COMBINATION;

AGED; ARTICLE; CLINICAL EFFECTIVENESS; DISEASE COURSE; FEMALE; HUMAN; JOINT SPACE WIDTH; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; PRIORITY JOURNAL; SUPPLEMENTATION; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; DIETARY SUPPLEMENT; DRUG COMBINATION; FOLLOW UP; KNEE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; CHONDROITIN; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GLUCOSAMINE; HUMANS; KNEE; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 84923621642     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38932     Document Type: Article

References (46)

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008; 58: 26-35.
2. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64: 465-74.
3. Lapane KL, Sands MR, Yang S, McAlindon TE, Eaton CB,. Use of complementary and alternative medicine among patients with radiographic-confirmed knee osteoarthritis. Osteoarthritis Cartilage 2012; 20: 22-8.
4. McCarty MF,. The neglect of glucosamine as a treatment for osteoarthritis-a personal perspective. Med Hypotheses 1994; 42: 323-7.
5. Sherman AL, Ojeda-Correal G, Mena J,. Use of glucosamine and chondroitin in persons with osteoarthritis. PM R 2012; 4 Suppl: S110-6.
6. Huskisson EC,. Glucosamine and chondroitin for osteoarthritis. J Int Med Res 2008; 36: 1161-79.
7. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: CD002946.
8. Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146: 580-90.
9. McAlindon TE, LaValley MP, Gulin JP, Felson DT,. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469-75.
10. Vlad SC, LaValley MP, McAlindon TE, Felson DT,. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 2007; 56: 2267-77.
11. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG,. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int 2010; 30: 357-63.
12. Hochberg MC,. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 2010; 18 Suppl 1: S28-31.
13. Wandel S, Juni P, Tendal B, Nuesch E, Villiger P, Welton N, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341: c4675.
14. Felson DT,. Chondroitin for pain in osteoarthritis [editorial]. Ann Intern Med 2007; 146: 611-2.
15. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-6.
16. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC,. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113-23.
17. Nevitt MC, Felson DT, Lester G,. The Osteoarthritis Initiative: protocol for the cohort study. June 2006. URL: http://oai.epi-ucsf.org/datarelease/docs/StudyDesignProtocol.pdf.
18. Nallamothu BK, Hayward RA, Bates ER,. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008; 118: 1294-303.
19. Martel-Pelletier J, Roubille C, Abram F, Hochberg MC, Dorais M, Delorme P, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2013. E-pub ahead of print.
20. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
21. Roos EM, Klassbo M, Lohmander LS,. WOMAC osteoarthritis index. Reliability, validity, and responsiveness in patients with arthroscopically assessed osteoarthritis. Scand J Rheumatol 1999; 28: 210-5.
22. Duryea J, Li J, Peterfy CG, Gordon C, Genant HK,. Trainable rule-based algorithm for the measurement of joint space width in digital radiographic images of the knee. Med Phys 2000; 27: 580-91.
23. Duryea J, Neumann G, Niu J, Totterman S, Tamez J, Dabrowski C, et al. Comparison of radiographic joint space width with magnetic resonance imaging cartilage morphometry: analysis of longitudinal data from the Osteoarthritis Initiative. Arthritis Care Res (Hoboken) 2010; 62: 932-7.
24. University of California San Francisco OAI Coordinating Center. Central assessment of longitudinal knee x-rays for quantitative JSW. June 2013. URL: https://oai.epi-ucsf.org/datarelease/SASDocs/kXR-QJSW-Duryea-descrip.pdf.
25. Okma-Keulen P, Hopman-Rock M,. The onset of generalized osteoarthritis in older women: a qualitative approach. Arthritis Rheum 2001; 45: 183-90.
26. Ware JE Jr, Kosinski M, Keller SD,. A 12-item Short Form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-33.
27. Reijman M, Pols HA, Bergink AP, Hazes JM, Belo JN, Lievense AM, et al. Body mass index associated with onset and progression of osteoarthritis of the knee but not of the hip: the Rotterdam Study. Ann Rheum Dis 2007; 66: 158-62.
28. Barnes PM, Bloom B, Nahin RL,. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008; 12: 1-23.
29. Greenland S, Finkle WD,. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 1995; 142: 1255-64.
30. Robins JM, Hernan MA, Brumback B,. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-60.
31. Hernan MA, Hernandez-Diaz S, Robins JM,. A structural approach to selection bias. Epidemiology 2004; 15: 615-25.
32. Platt RW, Brookhart M, Cole SR, Westreich D, Schisterman EF,. An information criterion for marginal structural models. Stat Med 2012; 32: 1383-93.
33. Cole SR, Hernan MA,. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168: 656-64.
34. Hernan MA, Brumback B, Robins JM,. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11: 561-70.
35. Greco NJ, Anderson AF, Mann BJ, Cole BJ, Farr J, Nissen CW, et al. Responsiveness of the International Knee Documentation Committee Subjective Knee Form in comparison to the Western Ontario and McMaster Universities Osteoarthritis Index, modified Cincinnati Knee Rating System, and Short Form 36 in patients with focal articular cartilage defects. Am J Sports Med 2010; 38: 891-902.
36. Angst F, Aeschlimann A, Stucki G,. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001; 45: 384-91.
37. Escobar A, Quintana JM, Bilbao A, Arostegui I, Lafuente I, Vidaurreta I,. Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement. Osteoarthritis Cartilage 2007; 15: 273-80.
38. Hunter DJ,. Risk stratification for knee osteoarthritis progression: a narrative review. Osteoarthritis Cartilage 2009; 17: 1402-7.
39. Vignon E, Piperno M, Le Graverand MP, Mazzuca SA, Brandt KD, Mathieu P, et al. Measurement of radiographic joint space width in the tibiofemoral compartment of the osteoarthritic knee: comparison of standing anteroposterior and Lyon schuss views. Arthritis Rheum 2003; 48: 378-84.
40. Pan W,. Akaike's information criterion in generalized estimating equations. Biometrics 2001; 57: 120-5.
41. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Harris CL, Singer NG, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010; 69: 1459-64.
42. Fransen M, Agaliotis M, Nairn L, Votrubec M, Bridgett L, Su S, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2014. E-pub ahead of print.
43. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO, Harris CL, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum 2008; 58: 3183-91.
44. Bland JM, Altman DG,. Multiple significance tests: the Bonferroni method. BMJ 1995; 310: 170.
45. Setoguchi S, Gerhard T,. Comparator selection. In:, Velentgas P, Dreyer NA, Nourjah P, editors. Developing a protocol for observational comparative effectiveness research: a user's guide. Rockville (MD): Agency for Healthcare Research and Quality; 2013. p. 59-70.
46. Russell AS, Aghazadeh-Habashi A, Jamali F,. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 2002; 29: 2407-9.